Subcutaneous Immunoglobulin (SCIg) therapy for hypogammaglobulinaemia secondary to malignancy or related drug therapy

Immunoglobulin replacement therapy (IRT) has an important role in minimising infections and improving the Health Related Quality of Life (HRQoL) in patients with immunodeficiency, who would otherwise experience recurrent infections. These plasma derived products are available as intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg). The global demand for these products is growing rapidly and has placed pressure on supply. Some malignancies and their treatment (as well as other medical therapies) can lead to secondary hypogammaglobulinaemia or secondary immunodeficiency (SID) requiring IRT.

Source: Transfusion Medicine Reviews - July 3, 2016 Category: Hematology Authors: Tanja M. Windegger, Christine A. Lambooy, Leanne Hollis, Karen Morwood, Helen Weston, Yoke L. Fung Source Type: research